Valuation: Myriad Genetics, Inc.

Market Cap 596M 521M 482M 442M 837M 57.43B 851M 5.75B 2.26B 28.04B 2.24B 2.19B 96.82B P/E 2026 *
-8.3x
P/E 2027 * -11.9x
Enterprise Value 596M 521M 482M 442M 837M 57.43B 851M 5.75B 2.26B 28.04B 2.24B 2.19B 96.82B EV / Sales 2026 *
0.69x
EV / Sales 2027 * 0.65x
Free-Float
96.24%
Yield 2026 *
-
Yield 2027 * -
1 day-2.30%
1 week+0.41%
Current month+7.27%
1 month+44.12%
3 months+22.50%
6 months+3.46%
Current year-0.41%
1 week 5.67
Extreme 5.67
6.43
1 month 4.22
Extreme 4.22
6.43
Current year 3.53
Extreme 3.53
7.15
1 year 3.53
Extreme 3.53
8.59
3 years 3.53
Extreme 3.53
29.3
5 years 3.53
Extreme 3.53
36.95
10 years 3.53
Extreme 3.53
50.44
Manager TitleAgeSince
Chief Executive Officer 54 30/04/2025
Director of Finance/CFO 43 16/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2026
Director TitleAgeSince
Chairman 67 23/03/2020
Director/Board Member 71 10/06/2010
Director/Board Member 66 25/09/2019
Date Insider Type Main position Quantity % Market Cap.
23/6/26 Other

Director

0 0%
11/6/26 Free

Executive/Senior Manager

5,000 0.0053%
11/6/26 Free

Chief Executive Officer

3,542 0.0038%
Change 5-day change 1-year change 3-year change Capi.($)
-2.30%+0.41%+21.05%-72.93% 596M
-4.31%-4.63%+227.31%+313.22% 21.61B
+1.18%+1.47%-38.55%-22.10% 9.69B
+1.05%-1.15%+40.80%+19.87% 6.79B
-5.55%-0.63%+246.24%-27.41% 5.81B
+2.44%+9.01%-16.48%-28.79% 5.1B
-5.84%-8.09%-47.69% - 4.94B
+0.46%+0.35%-21.31%-24.32% 4.21B
+7.48%+20.79%+83.44%+108.39% 4.15B
+2.00%+7.26%-11.87%-39.00% 2.74B
Average -0.37%+7.40%+48.29%+25.22% 6.56B
Weighted average by Cap. -1.34%+6.12%+93.90%+108.41%

Financials

2026 *2027 *
Net sales 864M 755M 698M 641M 1.21B 83.21B 1.23B 8.33B 3.27B 40.64B 3.24B 3.17B 140B 916M 801M 740M 679M 1.29B 88.25B 1.31B 8.83B 3.47B 43.09B 3.44B 3.36B 149B
Net income -71.48M -62.48M -57.78M -53.02M -100M -6.89B -102M -689M -271M -3.36B -268M -263M -11.61B -50.98M -44.56M -41.21M -37.81M -71.57M -4.91B -72.81M -491M -193M -2.4B -191M -187M -8.28B
Net Debt - -
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
17/07/26 USD 6.125 -2.93% 605,119
15/07/26 USD 6.310 +4.47% 1,100,550
14/07/26 USD 6.040 +3.07% 896,466
13/07/26 USD 5.860 +0.51% 811,599
10/07/26 USD 5.830 -4.43% 856,979
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
6.310USD
Average target price
6.250USD
Spread / Average Target
-0.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock